Encompass Health vs U.S. Physical Therapy: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Encompass Health Corp (EHC)

Q3 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

August 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

Latest1 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

U.S. Physical Therapy, Inc. (USPH)

Q3 20261 Aug – 14 Sep 2026

▲2

USPH grows visits and buys clinics, but costs squeeze profit

Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.

August 20261 Aug – 14 Sep 2026

▲2

USPH grows visits and buys clinics, but costs squeeze profit

Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.

Latest1 Aug – 14 Sep 2026

▲2

USPH grows visits and buys clinics, but costs squeeze profit

Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.